Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial

View ORCID ProfileFrancesco Perrone, Maria Carmela Piccirillo, Paolo Antonio Ascierto, Carlo Salvarani, Roberto Parrella, Anna Maria Marata, Patrizia Popoli, Laurenzia Ferraris, Massimiliano M. Marrocco-Trischitta, Diego Ripamonti, Francesca Binda, Paolo Bonfanti, Nicola Squillace, Francesco Castelli, Maria Lorenza Muiesan, Miriam Lichtner, Carlo Calzetti, Nicola Duccio Salerno, Luigi Atripaldi, Marco Cascella, Massimo Costantini, Giovanni Dolci, Nicola Cosimo Facciolongo, Fiorentino Fraganza, Marco Massari, Vincenzo Montesarchio, Cristina Mussini, Emanuele Alberto Negri, Gerardo Botti, Claudia Cardone, Piera Gargiulo, Adriano Gravina, Clorinda Schettino, Laura Arenare, View ORCID ProfilePaolo Chiodini, View ORCID ProfileCiro Gallo on behalf of the TOCIVID-19 investigators (see Appendix for a complete list), Italy
doi: https://doi.org/10.1101/2020.06.01.20119149
Francesco Perrone
1Clinical Trial Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Francesco Perrone
  • For correspondence: f.perrone@istitutotumori.na.it
Maria Carmela Piccirillo
1Clinical Trial Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paolo Antonio Ascierto
2Melanoma. Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlo Salvarani
3Università degli Studi di Modena e Reggio Emilia and Azienda USL-IRCCS di Reggio Emilia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roberto Parrella
4Cotugno Hospital, AORN Ospedali dei Colli, Napoli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Maria Marata
5Emilia Romagna Health Directorate, Bologna
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrizia Popoli
6Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Roma
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurenzia Ferraris
7Infectious Diseases Unit, Hospital Health Direction, IRCCS - Policlinico San Donato, Milano
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Massimiliano M. Marrocco-Trischitta
7Infectious Diseases Unit, Hospital Health Direction, IRCCS - Policlinico San Donato, Milano
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diego Ripamonti
8Infectious Diseases Unit - ASST Papa Giovanni XXIII, Bergamo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesca Binda
8Infectious Diseases Unit - ASST Papa Giovanni XXIII, Bergamo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paolo Bonfanti
9Infectious Diseases Unit, ASST Monza and University Milano Bicocca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicola Squillace
9Infectious Diseases Unit, ASST Monza and University Milano Bicocca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Castelli
10University of Brescia and ASST Spedali Civili, Brescia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Lorenza Muiesan
10University of Brescia and ASST Spedali Civili, Brescia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miriam Lichtner
11Sapienza University of Rome, Santa Maria Goretti Hospital, Latina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlo Calzetti
12Infectious Diseases and Hepatology Unit AOU Parma
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicola Duccio Salerno
13UOC Malattie Infettive e Tropicali, AOUI, Verona
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luigi Atripaldi
4Cotugno Hospital, AORN Ospedali dei Colli, Napoli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Cascella
14Anesthesia and Resuscitation Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Massimo Costantini
15Azienda USL-IRCCS di Reggio Emilia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giovanni Dolci
3Università degli Studi di Modena e Reggio Emilia and Azienda USL-IRCCS di Reggio Emilia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicola Cosimo Facciolongo
15Azienda USL-IRCCS di Reggio Emilia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fiorentino Fraganza
4Cotugno Hospital, AORN Ospedali dei Colli, Napoli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Massari
15Azienda USL-IRCCS di Reggio Emilia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincenzo Montesarchio
4Cotugno Hospital, AORN Ospedali dei Colli, Napoli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristina Mussini
16Università degli Studi di Modena e Reggio Emilia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emanuele Alberto Negri
15Azienda USL-IRCCS di Reggio Emilia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerardo Botti
1Clinical Trial Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia Cardone
1Clinical Trial Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Piera Gargiulo
1Clinical Trial Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adriano Gravina
1Clinical Trial Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clorinda Schettino
1Clinical Trial Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Arenare
1Clinical Trial Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paolo Chiodini
17Department of Mental Health and Preventive Medicine, Università degli Studi della Campania Luigi Vanvitelli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paolo Chiodini
Ciro Gallo
17Department of Mental Health and Preventive Medicine, Università degli Studi della Campania Luigi Vanvitelli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ciro Gallo
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6) which might be important in the pathogenesis of interstitial pneumonia.

Objective to evaluate efficacy of tocilizumab in COVID-19 pneumonia patients.

Design multicenter single-arm phase 2 trial, powered to detect 10% absolute lethality rate reduction at 14 and 30-days, with 20% and 35% expected rates. A consecutive prospective validation cohort was also evaluated.

Setting 185 Italian public hospitals, during coronavirus breakout.

Patients 1221 patients hospitalized with pneumonia, from March 19th to 24th, 2020.

Intervention tocilizumab 8 mg/kg, intravenously, one or two administrations with 12 hours interval.

Measurements lethality rates at 14 and 30-days; safety according to CTCAE.

Results 301 and 920 cases were available for intention-to-treat (ITT) analysis in phase 2 and validation cohorts. Due to delayed drug availability, 60% of patients received tocilizumab, and with some delays. In phase 2, 67 patients died; lethality rates were 18.4% (97.5%CI: 13.6-24.0, P=0.52) and 22.4% (97.5%CI: 17.2-28.3, P<0.001) at 14 and 30-days. Lower rates (15.6% and 20.0%) were reported in the modified ITT including only treated patients (mITT). Lethality rates in the validation cohort were smaller than in phase 2, at 14 and 30 days and in ITT and mITT populations. Multivariable logistic regression model suggests tocilizumab be more effective in patients not requiring mechanical respiratory support at baseline. No relevant signal of specific drug toxicity was reported, many severe adverse events being disease-related.

Limitations single-arm design. In addition, delayed availability of the drug induced indication bias and immortal time bias.

Conclusion Tocilizumab reduced lethality rate at 30 but not at 14-days, compared with the expectations, without significant toxicity. Efficacy was more evident among patients not requiring mechanical respiratory support.

Registration EudraCT (2020-001110-38); clinicaltrials.gov (NCT04317092)

Funding No specific funding was available for the study. Tocilizumab was provided by Roche free of charge.

Competing Interest Statement

Dr. Perrone reports grants, personal fees and non-financial support from Bayer; grants and personal fees from Incyte, Astra Zeneca, Pierre Fabre; personal fees from Celgene, Janssen Cilag, Roche, Pfizer, Sandoz, outside the submitted work. Dr. Piccirillo reports grants and personal fees from AstraZeneca; grants from Roche; personal fees from Daichii Sankyo, GSK, MSD; non-financial support from Bayer, outside the submitted work. Dr. Ascierto reports grants and personal fees from BMS, Roche-Genentech, Array; personal fees and other from MSD; personal fees from Novartis, Merck Serono, Pierre Fabre, Incyte, Genmab, NewLink Genetics, Medimmune, AstraZeneca, Syndax, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer-Ingelheim, outside the submitted work. Dr. Salvarani reports grants and personal fees from Roche; personal fees from Sanofi-Genzyme, Abbvie, Pfizer, Eli-Lilly, Novartis, outside the submitted work. Dr. Castelli reports grants from Gilead, ViiV, GSK, Janssen, Eiger, Roche, Gilead, outside the submitted work. Dr. Gravina reports non-financial support from Pfizer, outside the submitted work. Dr. Lichtner reports grants from Gilead; personal fees from Abbvie, Merck, Janseen, Angelini, outside the submitted work.

Clinical Trial

NCT04317092

Clinical Protocols

http://www.repo.epiprev.it/1604

http://www.repo.epiprev.it/1610

Funding Statement

No specific funding was available for this study. Tocilizumab was provided by the pharmaceutical company (Roche) free of charge. The National Cancer Institute of Naples was the sponsor of the study and had full property of data and full access to them and final responsibility for the decision to submit for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

According to a specific Italian law, TOCIVID-19 was approved for all Italian centers by the National Ethical Committee at the Lazzaro Spallanzani Institute on March 18th, 2020; two amendments followed on March 24th, 2020 and April 28th, 2020.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data will be made available in the near future.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted June 05, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial
Francesco Perrone, Maria Carmela Piccirillo, Paolo Antonio Ascierto, Carlo Salvarani, Roberto Parrella, Anna Maria Marata, Patrizia Popoli, Laurenzia Ferraris, Massimiliano M. Marrocco-Trischitta, Diego Ripamonti, Francesca Binda, Paolo Bonfanti, Nicola Squillace, Francesco Castelli, Maria Lorenza Muiesan, Miriam Lichtner, Carlo Calzetti, Nicola Duccio Salerno, Luigi Atripaldi, Marco Cascella, Massimo Costantini, Giovanni Dolci, Nicola Cosimo Facciolongo, Fiorentino Fraganza, Marco Massari, Vincenzo Montesarchio, Cristina Mussini, Emanuele Alberto Negri, Gerardo Botti, Claudia Cardone, Piera Gargiulo, Adriano Gravina, Clorinda Schettino, Laura Arenare, Paolo Chiodini, Ciro Gallo
medRxiv 2020.06.01.20119149; doi: https://doi.org/10.1101/2020.06.01.20119149
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial
Francesco Perrone, Maria Carmela Piccirillo, Paolo Antonio Ascierto, Carlo Salvarani, Roberto Parrella, Anna Maria Marata, Patrizia Popoli, Laurenzia Ferraris, Massimiliano M. Marrocco-Trischitta, Diego Ripamonti, Francesca Binda, Paolo Bonfanti, Nicola Squillace, Francesco Castelli, Maria Lorenza Muiesan, Miriam Lichtner, Carlo Calzetti, Nicola Duccio Salerno, Luigi Atripaldi, Marco Cascella, Massimo Costantini, Giovanni Dolci, Nicola Cosimo Facciolongo, Fiorentino Fraganza, Marco Massari, Vincenzo Montesarchio, Cristina Mussini, Emanuele Alberto Negri, Gerardo Botti, Claudia Cardone, Piera Gargiulo, Adriano Gravina, Clorinda Schettino, Laura Arenare, Paolo Chiodini, Ciro Gallo
medRxiv 2020.06.01.20119149; doi: https://doi.org/10.1101/2020.06.01.20119149

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (230)
  • Allergy and Immunology (507)
  • Anesthesia (111)
  • Cardiovascular Medicine (1258)
  • Dentistry and Oral Medicine (207)
  • Dermatology (148)
  • Emergency Medicine (283)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (538)
  • Epidemiology (10048)
  • Forensic Medicine (5)
  • Gastroenterology (502)
  • Genetic and Genomic Medicine (2482)
  • Geriatric Medicine (239)
  • Health Economics (482)
  • Health Informatics (1653)
  • Health Policy (757)
  • Health Systems and Quality Improvement (638)
  • Hematology (250)
  • HIV/AIDS (536)
  • Infectious Diseases (except HIV/AIDS) (11889)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (255)
  • Medical Ethics (75)
  • Nephrology (269)
  • Neurology (2301)
  • Nursing (140)
  • Nutrition (354)
  • Obstetrics and Gynecology (458)
  • Occupational and Environmental Health (537)
  • Oncology (1258)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (326)
  • Pediatrics (737)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2294)
  • Public and Global Health (4850)
  • Radiology and Imaging (846)
  • Rehabilitation Medicine and Physical Therapy (493)
  • Respiratory Medicine (654)
  • Rheumatology (288)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (228)
  • Surgery (273)
  • Toxicology (44)
  • Transplantation (130)
  • Urology (100)